Nonfactor therapies may reduce costs associated with bleeding-related hospitalizations and use of bypassing agents. One study ...

Following achievement of the Return Cap, a royalty-only tail period will commence, which entitles HCRx to a predefined, reduced share of royalties not to exceed $14.9 million per year; the tail period ...

According to DataM Intelligence, the Intraoperative Radiation Therapy Market is experiencing rapid technological and clinical adoption, underpinned by the surge in global cancer prevalence and a ...

Selective autophagy ensures the targeted degradation of damaged or surplus cellular components, including organelles, thereby ...

By blade type, detachable designs account for 30.1% of market share due to their hygiene and versatility, while ceramic blades are gaining traction for their superior durability and heat resistance, ...